Seclidemstat (SP-2577)

Seclidemstat (SP-2577) is a potent and orally bioavailable inhibitor of lysine-specific demethylase 1 (LSD1/KDM1A) with IC50 of 13 nM. Seclidemstat (SP-2577) has potential antineoplastic activity.

此产品仅用于科学研究，我们不为任何个人用途提供产品和服务

库存: 现货

可选规格

包装

价格

促销价

数量
1mg

￥775.00

620.00

- +
5mg

￥1900.00

1520.00

- +
10mg

￥3012.00

2410.00

- +
25mg

￥5987.00

4790.00

- +
50mg

￥9175.00

7340.00

- +
100mg

￥13887.00

11110.00

- +

已选 0 种 0 瓶

金额: ￥0.00

首页收藏

货号: ajce49882
CAS: 1423715-37-0
别名: SP-2577
分子式: C20H23ClN4O4S
分子量: 450.94
纯度: >98%
溶解度: DMSO : 100 mg/mL (221.76 mM);Water : < 0.1 mg/mL (insoluble)
储存: Store at -20°C
库存: 现货

Background

Seclidemstat (SP-2577) is a potent and orally bioavailable inhibitor of lysine-specific demethylase 1 (LSD1/KDM1A) with IC50 of 13 nM. Seclidemstat (SP-2577) has potential antineoplastic activity.

The combination therapy of Seclidemstat (SP-2577) with checkpoint inhibitors may induce or augment immunogenic responses of SWI/SNF-mutated ovarian cancers. Seclidemstat promotes endogenous retroviruses (ERVs) expression and activation of IFNβ pathway in small cell carcinoma of the ovary hypercalcemic type (SCCOHT) cell lines. Seclidemstat (3 μM) promotes PD-L1 expression in SCCOHT COV 434 pIND 20 BRG1-2.7 cell line.[1]

[1] Soldi R, et al. PLoS One. 2020 Jul 10;15(7):e0235705. [2] Hariprasad V, et al. WO 2017004519 A1.